IN8bio (INAB) Competitors $2.23 +0.07 (+3.24%) Closing price 07/3/2025 03:44 PM EasternExtended Trading$2.17 -0.06 (-2.87%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INAB vs. KALA, ALXO, ENLV, GBIO, TPST, DARE, SNYR, CARA, PASG, and CVKDShould you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include KALA BIO (KALA), ALX Oncology (ALXO), Enlivex Therapeutics (ENLV), Generation Bio (GBIO), Tempest Therapeutics (TPST), Dare Bioscience (DARE), Synergy CHC (SNYR), Cara Therapeutics (CARA), Passage Bio (PASG), and Cadrenal Therapeutics (CVKD). These companies are all part of the "pharmaceutical products" industry. IN8bio vs. Its Competitors KALA BIO ALX Oncology Enlivex Therapeutics Generation Bio Tempest Therapeutics Dare Bioscience Synergy CHC Cara Therapeutics Passage Bio Cadrenal Therapeutics KALA BIO (NASDAQ:KALA) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation. Is KALA or INAB more profitable? IN8bio's return on equity of -218.85% beat KALA BIO's return on equity.Company Net Margins Return on Equity Return on Assets KALA BION/A -369.29% -64.99% IN8bio N/A -218.85%-139.59% Do analysts recommend KALA or INAB? KALA BIO presently has a consensus price target of $13.50, indicating a potential upside of 155.20%. IN8bio has a consensus price target of $180.00, indicating a potential upside of 7,971.75%. Given IN8bio's higher possible upside, analysts plainly believe IN8bio is more favorable than KALA BIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KALA BIO 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00IN8bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to KALA or INAB? In the previous week, KALA BIO had 1 more articles in the media than IN8bio. MarketBeat recorded 2 mentions for KALA BIO and 1 mentions for IN8bio. KALA BIO's average media sentiment score of 0.63 beat IN8bio's score of 0.00 indicating that KALA BIO is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KALA BIO 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IN8bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation and earnings, KALA or INAB? IN8bio has lower revenue, but higher earnings than KALA BIO. KALA BIO is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKALA BIO$3.89M8.77-$38.51M-$8.24-0.64IN8bioN/AN/A-$30.44M-$13.57-0.16 Do institutionals and insiders believe in KALA or INAB? 24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 8.3% of KALA BIO shares are owned by insiders. Comparatively, 15.5% of IN8bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryKALA BIO and IN8bio tied by winning 6 of the 12 factors compared between the two stocks. Get IN8bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INAB vs. The Competition Export to ExcelMetricIN8bioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.60M$2.91B$5.54B$9.05BDividend YieldN/A2.44%5.24%4.02%P/E Ratio-0.1621.5627.4320.23Price / SalesN/A281.76422.11118.64Price / CashN/A42.7336.8958.07Price / Book0.377.518.045.67Net Income-$30.44M-$55.05M$3.18B$249.13M7 Day Performance4.69%4.61%2.89%3.28%1 Month Performance-38.11%4.72%3.70%5.56%1 Year Performance-90.71%5.92%36.15%21.12% IN8bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INABIN8bio2.5918 of 5 stars$2.23+3.2%$180.00+7,971.7%-90.7%$6.60MN/A-0.1620KALAKALA BIO3.7924 of 5 stars$4.02-0.5%$13.50+235.8%-22.4%$26.07M$3.89M-0.4930ALXOALX Oncology2.6633 of 5 stars$0.46-5.0%$3.30+617.9%-91.6%$25.84MN/A-0.1940Negative NewsENLVEnlivex Therapeutics3.1894 of 5 stars$1.16+6.4%$10.00+762.1%-11.7%$25.78MN/A-1.7670GBIOGeneration Bio2.9795 of 5 stars$0.36-5.3%$7.33+1,937.6%-85.7%$25.47M$19.89M-0.33150TPSTTempest Therapeutics1.7943 of 5 stars$6.85+1.0%$30.00+338.0%-74.0%$24.97MN/A-0.3820News CoverageDAREDare Bioscience1.6094 of 5 stars$2.56-9.2%$12.00+368.8%-22.3%$24.96M$10K-15.0630News CoverageHigh Trading VolumeSNYRSynergy CHC3.7715 of 5 stars$2.57-3.0%$10.00+289.1%N/A$24.36M$34.83M0.0040Gap UpCARACara Therapeutics0.354 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580News CoverageGap DownHigh Trading VolumePASGPassage Bio3.079 of 5 stars$0.33-14.4%$7.50+2,140.1%-48.3%$24.30MN/A-0.33130Gap UpCVKDCadrenal Therapeutics3.042 of 5 stars$11.44-7.4%$32.00+179.7%N/A$24.29MN/A0.004Gap Down Related Companies and Tools Related Companies KALA Competitors ALXO Competitors ENLV Competitors GBIO Competitors TPST Competitors DARE Competitors SNYR Competitors CARA Competitors PASG Competitors CVKD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INAB) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IN8bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IN8bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
